22
ResearchNoble & Aptar Pharma to launch AdhereITNoble and Aptar Pharma have announced the launch ofAdhereIT — a connected, intuitive and user-friendlyonboarding solution for the growing number of patients withchronic conditions who use autoinjectors to administer theirmedications at home. AdhereIT is the rst fullyinterchangeable, connected add-on solution that can workacross a multitude of autoinjector platforms. This launch is animportant advancement for Noble, an Aptar Pharma company,whose mission is to foster healthy outcomes for patients whoself-administer their therapies, partnering with pharma andbiotech companies to provide robust training devices andonboarding programs.Adherence to prescribed biologics is a signi cant challenge. Arecent report in the Journal of the American Academy ofDermatology reported that 45% of studied patients sufferingfrom psoriasis discontinue their treatments. The reasonsinclude insufficient training or time with an instructor, lack ofcon dence during the self-injection process, and feelings ofhigh anxiety and lack of control. COVID-19 has contributed tothe increased utilization of telemedicine and remotehealthcare, which has even further complicated this challengeby reducing healthcare professional (HCP) trainingopportunities with patients.AdhereIT is part of the digital ecosystem that enablespatients to gain control and con dence over their at-homedrug delivery while easing the anxiety associated with selfinjecting.AdhereIT integrates with the existing softwareapplications developed by the Digital Healthcare team atAptar Pharma by pairing a patient's autoinjector via Bluetoothtechnology to their mobile phone. The device — available intwo design options to accommodate dexterity for a onehandedor two-handed injection process — precisely detectsan injection event and provides real-time visual, audio andhaptic feedback about whether the injection was performedc o r r e c t l y . T h e A d h e r e I T onboarding platform also allowsHCPs to monitor their patients'therapeutic performance via asmar t analytical dashboard,providing valuable patientspecic adherence behaviorinformation.“ We are excited to welcomeNoble's AdhereIT connectedonboarding platform into the suite of Aptar Pharma's DigitalHealthcare solutions. This innovative technology furtherenhances our ability to improve patients' lives by creating aseamless integration of injectable products into our diseasemanagement offerings,” said Adam Shain, Director of BusinessDevelopment for Digital Healthcare, Aptar Pharma.Noble developed AdhereIT in partnership with AptarPharma, who has made signi cant investments in digitalhealthcare over the past three years to actively develop aportfolio of disease management platforms and connecteddevice solutions across dermal, pulmonary, nasal, ophthalmicand injectable routes of administration.“Connected medical devices represent the future ofhealthcare for patients, pharmaceutical companies, healthinsurers and HCPs, playing a vital role in the remote trackingand treatment of chronic illnesses, and delivering a range ofbene ts that include improved drug management, enrichedpatient experiences and enhanced patient outcomes,” said TimMcLeroy, Noble's Executive Director of Marketing & PatientServices. “The connectivity of digital technology solutions likeAdhereIT also create market differentiation and enablevalue-based contracting for biopharmaceutical companiesand medical device manufacturers to survive in a competitiveand challenging marketplace.”Teleflex launches Urolift Advanced TissueControl system to treat patients with BPHT e l e e x h a slaunched theU r o l i f tA d v a n c e dTissue Controls y s t e m , ap r o d u c td e s i g n e d t otreat patientswith benign prostatic hyperplasia (BPH). The system can beused to open the urethra by inserting small implants that holdthe lobes of the prostrate in a retracted position. The device isspeci cally tailored to treat those with challenging prostaticanatomy, including those with large lateral lobes and anobstructive median lobe.BPH is a common condition affecting perhaps over 500 millionmen globally, and it often occurs with increasing age. For menwho are affected, it can lead to a decreased quality of life.Treatments include medication or surgical intervention, butthese approaches don't always work well for everyone.The Urolift system aims to provide a minimally invasiveapproach to treating the condition, and does not require anincision or destructive enlargement of the urethra. Patientscan be treated in an outpatient procedure that takes onlyabout an hour or two. A urologist can advance the device intothe urethra under cystoscopic visualization, and then use it toinsert small implants around the enlarged prostatic lobes,pushing them aside to create more space.Tissue control wings that help to hold tissue back during theprocedure are included in the new system, helping theurologist to visualize the blockage more easily. The device tiphas also been enhanced, making it easier to deliver theimplants. Laser-etched indicators on the needle locationmarker also help to predictably place the implants.“We are encouraged by early positive responses fromurologists to the UroLift ATC System,” said Dave Amerson,president of the Tele ex Interventional Urology business unit,in an announcement. “Urologists are reporting highsatisfaction with its ease of use and indicating their willingnessto adopt the new device in their practices to treat patients withchallenging anatomies, including obstructive median lobeand large lateral lobes.”23Mediworldme